Skip to main content
SpringerLink
Log in
Book cover

Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders pp 1–18Cite as

Ocular Allergy

  • Chapter
  • First Online:

  • 714 Accesses

Abstract

Allergy is a pathologic condition that can occur in genetically predisposed individuals who generate an aberrant immune response against environmental antigens, defined allergens. This immune response is characterized by the differentiation of T-helper (Th) cells in the Th type 2 (Th2) cell and by the production of allergen-specific IgE.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   64.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Abelson MB. A review of olopatadine for the treatment of ocular allergy. Expert Opin Pharmacother. 2004;5:1979–94.

    Article  CAS  PubMed  Google Scholar 

  2. Abu El Asrar AM, Al-Kharashi SA, Al-Mansouri S, et al. Langerhans’ cells in vernal keratoconjunctivitis express the costimulatory molecule B7–2 (CD86) but not B7–1 (CD80). Eye. 2001;15:648–54.

    Article  CAS  PubMed  Google Scholar 

  3. Akpek EK, Dart JK, Watson S, et al. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology. 2004;111:476–82.

    Article  PubMed  Google Scholar 

  4. Akpek EK, Hasiripi H, Christen WG, et al. A randomized trial of low-dose, topical mitomycin-C in the treatment of severe vernal keratoconjunctivitis. Ophthalmology. 2000;107:263–9.

    Article  CAS  PubMed  Google Scholar 

  5. Belfair N, Monos T, Levy J, et al. Removal of giant vernal papillae by CO2 laser. Can J Ophthalmol. 2005;40:472–6.

    Article  PubMed  Google Scholar 

  6. BenEzra D. Classification of conjunctivitis and blepharitis. In: BenEzra D, editor. Blepharitis and conjunctivitis. Guidelines for diagnosis and treatment. Barcelona: Editorial Glosa; 2006.

    Google Scholar 

  7. BenEzra D, Pe’er J, Brodsky M, Cohen E. Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis. Am J Ophthalmol. 1986;101:278–82.

    CAS  PubMed  Google Scholar 

  8. Bielory L. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann Allergy Asthma Immunol. 2008;100:272–9.

    Article  CAS  PubMed  Google Scholar 

  9. Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs. 2005;65:215–28.

    Article  CAS  PubMed  Google Scholar 

  10. Bonini S, Bonini S, Lambiase A, et al. Vernal keratoconjunctivitis revisited. A case series of 195 patients with long-term follow up. Ophthalmology. 2000;107:1157–63.

    Article  CAS  PubMed  Google Scholar 

  11. Bonini S, Micera A, Iovieno A, et al. Expression of Toll-like receptors in healthy and allergic conjunctiva. Ophthalmology. 2005;112:1548–9.

    Article  Google Scholar 

  12. Cetinkaya A, Akova YA, Dursun D, et al. Topical cyclosporine in the management of shield ulcers. Cornea. 2004;23:194–200.

    Article  PubMed  Google Scholar 

  13. Cook EB, Stahl JL, Barney NP, et al. Mechanisms of antihistamines and mast cell stabilizers in ocular allergic inflammation. Curr Drug Targets Inflamm Allergy. 2002;1:167–80.

    Article  CAS  PubMed  Google Scholar 

  14. Cornish KS, Gregory ME, Ramaesh K. Systemic cyclosporin A in severe atopic keratoconjunctivitis. Eur J Ophthalmol. 2010;20:844–51.

    PubMed  Google Scholar 

  15. Daniell M, Constantinou M, Vu HT, et al. Randomized controlled trial of cyclosporine A in steroid dependent allergic conjunctivitis. Br J Ophthalmol. 2006;90:461–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Foster CS, Calonge M. Atopic keratoconjunctivitis. Ophthalmology. 1990;97:992–1000.

    Article  CAS  PubMed  Google Scholar 

  17. Fujishima H, Fukagawa K, Satake Y, et al. Combined medical and surgical treatment of severe vernal keratoconjunctivitis. Jpn J Ophthalmol. 2000;44:511–5.

    Article  CAS  PubMed  Google Scholar 

  18. Fukushima A, Yamaguchi T, Sumi T, et al. Roles of CD4 + CD25+ T cells in the development of experimental murine allergic conjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2007;245:705–14.

    Article  CAS  PubMed  Google Scholar 

  19. García DP, Alperte JI, Cristóbal JA, et al. Topical tacrolimus ointment for treatment of intractable atopic keratoconjunctivitis: a case report and review of the literature. Cornea. 2011;30:462–5.

    Article  PubMed  Google Scholar 

  20. Hingorani M, Calder VL, Buckley RJ, et al. The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis. Invest Ophthalmol Vis Sci. 1999;40:392–9.

    CAS  PubMed  Google Scholar 

  21. Hoang-Xuan T, Prisant O, Hannouche D, Robin H. Systemic cyclosporine A in severe atopic keratoconjunctivitis. Ophthalmology. 1997;104:1300–5.

    Article  CAS  PubMed  Google Scholar 

  22. Irkec MT, Orhan M, Erdener U. Role of tear inflammatory mediators in contact lens-associated giant papillary conjunctivitis in soft contact lens wearers. Ocul Immunol Inflamm. 1999;7:35–8.

    Article  CAS  PubMed  Google Scholar 

  23. Johansson SG, Hourihane JO, Bousquet J, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy. 2001;56:813–24.

    Article  CAS  PubMed  Google Scholar 

  24. Kheirkhah A, Zavareh MK, Farzbod F, Mahbod M, Behrouz MJ. Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis. Eye (Lond). 2011;25(7):872–80.

    Article  CAS  Google Scholar 

  25. Kilic A, Gurler B. Topical 2% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis. Can J Ophthalmol. 2006;41:693–8.

    Article  PubMed  Google Scholar 

  26. Kumagai N, Fukuda K, Fujitsu Y, et al. Role of structural cells of the cornea and conjunctiva in the pathogenesis of vernal keratoconjunctivitis. Prog Retin Eye Res. 2006;25:165–87.

    Article  CAS  PubMed  Google Scholar 

  27. Lambiase A, Normando EM, Vitiello L, et al. Natural killer cells in vernal keratoconjunctivitis. Mol Vis. 2007;13:1562–7.

    CAS  PubMed  Google Scholar 

  28. Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Retin Eye Res. 2002;21:319–39.

    Article  CAS  PubMed  Google Scholar 

  29. Leonardi A, Brun P, Abatangelo G, et al. Tear levels and activity of matrix metalloproteinase (MMP)-1 and MMP-9 in vernal keratoconjunctivitis. Invest Ophthalmol Vis Sci. 2003;44:3052–8.

    Article  PubMed  Google Scholar 

  30. Leonardi A, Sathe S, Bortolotti M, Beaton A, Sack R. Cytokines, matrix metalloproteases, angiogenic and growth factors in tears of normal subjects and vernal keratoconjunctivitis patients. Allergy. 2009;64:710–7.

    Article  CAS  PubMed  Google Scholar 

  31. Macejko TT, Bergmann MT, Williams JI, et al. Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis. Am J Ophthalmol. 2010;150:122–7.e125.

    Article  CAS  PubMed  Google Scholar 

  32. Maggi L, Santarlasci V, Liotta F, et al. Demonstration of circulating allergen-specific CD4 + CD25highFoxp3+ T-regulatory cells in both nonatopic and atopic individuals. J Allergy Clin Immunol. 2007;120:429–36.

    Article  CAS  PubMed  Google Scholar 

  33. Mantelli F, Santos MS, Petitti T, et al. Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis. Br J Ophthalmol. 2007;91:1656–61.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Manzouri B, Flynn T, Ohbayashi M, et al. The dendritic cell in allergic conjunctivitis. Ocul Surf. 2008;6:70–8.

    Article  PubMed  Google Scholar 

  35. Manzouri B, Ohbayashi M, Leonardi A, et al. Characterization of dendritic cell phenotype in allergic conjunctiva: increased expression of FcvarepsilonRI, the high-affinity receptor for immunoglobulin E. Eye. 2008;94:1662–7.

    Google Scholar 

  36. Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, et al. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology. 2008;115:988–99.

    Article  PubMed  Google Scholar 

  37. Nivenius E, Montan PG, Chryssanthou E, et al. No apparent association between periocular and ocular microcolonization and the degree of inflammation in patients with atopic keratoconjunctivitis. Clin Exp Allergy. 2004;34:725–30.

    Article  CAS  PubMed  Google Scholar 

  38. Nivenius E, van der Ploeg I, Jung K, et al. Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis. Eye. 2007;21:968–75.

    Article  CAS  PubMed  Google Scholar 

  39. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol. 2005;115:118–22.

    Article  CAS  PubMed  Google Scholar 

  40. Origlieri C, Bielory L. Intranasal corticosteroids and allergic rhinoconjunctivitis. Curr Opin Allergy Clin Immunol. 2008;8:450–6.

    Article  CAS  PubMed  Google Scholar 

  41. Ozcan AA, Ersoz TR, Dulger E. Management of severe allergic conjunctivitis with topical cyclosporin a 0.05% eyedrops. Cornea. 2007;26:1035–8.

    Article  PubMed  Google Scholar 

  42. Pelegrin L, Gris O, Adán A, et al. Superficial keratectomy and amniotic membrane patch in the treatment of corneal plaque of vernal keratoconjunctivitis. Eur J Ophthalmol. 2008;18:131–3.

    CAS  PubMed  Google Scholar 

  43. Pucci N, Novembre E, Cianferoni A, et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol. 2002;89:298–303.

    Article  CAS  PubMed  Google Scholar 

  44. Reinhard T, Möller M, Sundmacher R. Penetrating keratoplasty in patients with atopic dermatitis with and without systemic cyclosporin A. Cornea. 1999;18:645–51.

    Article  CAS  PubMed  Google Scholar 

  45. Rikkers SM, Holland GN, Drayton GE, et al. Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol. 2003;135:297–302.

    Article  CAS  PubMed  Google Scholar 

  46. Röder E, Berger MY, de Groot H, et al. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. Pediatr Allergy Immunol. 2008;19:197–207.

    Article  PubMed  Google Scholar 

  47. Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol. 1990;110:137–42.

    Google Scholar 

  48. Shulman DG, Lothringer LL, Rubin JM, et al. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology. 1999;106:362–9.

    Article  CAS  PubMed  Google Scholar 

  49. Spadavecchia L, Fanelli P, Tesse R, et al. Efficacy of 1.25% and 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood. Pediatr Allergy Immunol. 2006;17:527–32.

    Article  PubMed  Google Scholar 

  50. Stumpf T, Luqmani N, Sumich P, et al. Systemic tacrolimus in the treatment of severe atopic keratoconjunctivitis. Cornea. 2006;25:1147–9.

    Article  PubMed  Google Scholar 

  51. Sumi T, Fukushima A, Fukuda K, et al. Differential contributions of B7-1 and B7-2 to the development of murine experimental allergic conjunctivitis. Immunol Lett. 2007;108:62–7.

    Article  CAS  PubMed  Google Scholar 

  52. Tanaka M, Takano Y, Dogru M, et al. A comparative evaluation of the efficacy of intraoperative mitomycin C use after the excision of cobblestone-like papillae in severe atopic and vernal keratoconjunctivitis. Cornea. 2004;23:326–9.

    Article  PubMed  Google Scholar 

  53. Toda M, Ono SJ. Genomics and proteomics of allergic disease. Immunology. 2002;106:1–10.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  54. Torkildsen GL, Ousler 3rd GW, et al. Ocular comfort and drying effects of three topical antihistamine/mast cell stabilizers in adults with allergic conjunctivitis: a randomized, double-masked crossover study. Clin Ther. 2008;30:1264–71.

    Article  CAS  PubMed  Google Scholar 

  55. Torkildsen G, Shedden A. The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis. Curr Med Res Opin. 2011;27:623–31.

    Article  CAS  PubMed  Google Scholar 

  56. Torkildsen GL, Williams JI, Gow JA, et al. Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge. Ann Allergy Asthma Immunol. 2010;105:57–64.

    Article  CAS  PubMed  Google Scholar 

  57. Utine CA, Stern M, Akpek EK. Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm. 2010;18:352–61.

    Article  CAS  PubMed  Google Scholar 

  58. Varadaradjalou S, Feger F, Thieblemont N, et al. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol. 2003;33:899–906.

    Article  CAS  PubMed  Google Scholar 

  59. Vichyanond P, Tantimongkolsuk C, Dumrongkigchaiporn P, et al. Vernal keratoconjunctivitis: result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment. J Allergy Clin Immunol. 2004;113:355–8.

    Article  PubMed  Google Scholar 

  60. Virtanen HM, Reitamo S, Kari M, et al. Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study. Acta Ophthalmol Scand. 2006;84:693–5.

    Article  CAS  PubMed  Google Scholar 

  61. Wilson FM. Allergy to topical medication. Int Ophthalmol Clin. 2003;43:73–81.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuroscience, Ophthalmology Unit, University of Padua, Via Giustiniani 2, Padua, 35128, Italy

    Andrea Leonardi MD

  2. Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Science – Ophthalmology, 2880 University Avenue, Madison, WI, 53705, USA

    Neal P. Barney MD

Authors
  1. Andrea Leonardi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neal P. Barney MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Leonardi MD .

Editor information

Editors and Affiliations

  1. Department of Ophthalmology, Charité Campus Virchow-Klinikum, Berlin, Germany

    Uwe Pleyer

  2. Division of Ophthalmology, Miguel Hernandez University, Vissum-Instituto Oftalmologico de Alicante, Alicante, Spain

    Jorge L. Alió

  3. Centre of Ocular Inflammation and Infection OCUVAC, Medical University of Vienna Laura Bassi Centre of Expertise, Vienna, Austria

    Talin Barisani-Asenbauer

  4. Department of Ophthalmology, Pitié-Salpêtrière’s University Hospital, Paris, France

    Phuc Le Hoang

  5. Doheny Eye Institute, University of Southern California Keck School of Medicine, Los Angeles, California, USA

    Narsing A. Rao

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Leonardi, A., Barney, N.P. (2014). Ocular Allergy. In: Pleyer, U., Alió, J., Barisani-Asenbauer, T., Le Hoang, P., Rao, N. (eds) Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54350-0_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54350-0_1

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-54349-4

  • Online ISBN: 978-3-642-54350-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation